drugset / Trial / NCT04104997

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

NCT04104997 ↗

Phase 1 Completed 39 enrolled GL Pharm Tech Corporation
RandomizedSequentialDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of GLH8NDE after single and multiple ocular administrations in healthy Korean and Caucasian volunteers

Timeline

Start
2019-09-26
Primary completion
2020-02-18
Completion
2020-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GLH8NDE Unknown 5 % Topical

Indications